Vildagliptin - Uses - Dosages - Side Effects - Precautions

Vildagliptin: Frequently Asked Questions Answered

What is Vildagliptin?

Vildagliptin is an oral enemy of diabetic prescription that restrains dipeptidyl peptidase-4 (DPP-4). This oral enemy of diabetic specialists upgrades the responsiveness of pancreatic islet cells to glucose. Vildagliptin forestalls DPP-4 from inactivating glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This prompts a two-overlap activity in the pancreas, where GLP-1 and GIP stifle glucagon discharge by alpha cells and potentiate insulin emission by beta cells. Vildagliptin is promoted as Galvus and Eucreas.

What are the uses of Vildagliptin?

Vildagliptin is utilized to treat Type II diabetes mellitus as monotherapy, where insulinotropic impact and GLP-1 discharge are debilitated. This further develops glucose control in grown-ups with Type II diabetes with a standard eating regimen and exercise. Vildagliptin makes the pancreas discharge more insulin and diminishes the chemicals that expand the sugar levels in the blood. Utilizing this will decrease fasting and post-dinner sugar levels.

Book Doctor Appointment
Book Online Doctor Appointment
Search Specialty Doctor
Health Packages

What are the side effects of Vildagliptin?

Here are some of the standard and significant side effects of using Vildagliptin:

  1. Excessive sweating.
  2. Headache.
  3. Constipation.
  4. Hypoglycaemia.
  5. Heartburn.
  6. Cough.
  7. Swelling of eyelids, lips, and face.
  8. Weakness.
  9. Sweating.

Common side effects do not need any particular medical attention. They disappear as your body adjusts to the dosage. However, if you face any severe or rare impacts, it is ideal to consult our experts at Yashoda Hospitals or obtain a medical opinion.


Frequently Asked Questions about Vildagliptin

1. Is Vildagliptin FDA approved?

Vildagliptin is FDA (Food and Drug Administration) approved. The manufacturer received an approval letter from FDA in late February 2007. Though Vildagliptin is currently available in many countries, it is commercially undeveloped in the USA.

2. Is Vildagliptin the same as Sitagliptin?

Vildagliptin is not the same as Sitagliptin. The usage of 50 mg Sitagliptin once a day results in around 70% suppression of DPP-4 activity over 24 hours. Whereas the use of 50 mg Vildagliptin twice a day results in more than 80% suppression of DPP-4 activity. This is the difference in drug efficiency.

3. Can we take Vildagliptin in the afternoon?

If you are advised one dose a day, it is recommended you take it in the morning. And if advised two doses a day, take one in the morning and the other in the evening. Vildagliptin can be taken before, during, or after meals.

4. Does Vildagliptin cause weight gain?

Vildagliptin does not cause any weight gain. In general, Vildagliptin is weight-neutral. But in patients with relatively low baseline glycemia, modest weight loss has been observed. The weight neutrality observed with vildagliptin is a class effect of DPP-4 inhibitors. Without significant body weight changes, Vildagliptin improves glycemic control, as both monotherapy and add-on therapy to other oral agents.

5. How long does it take to acton Vildagliptin?

In the state of fasting, Vildagliptin is absorbed soon after oral administration. Peak plasma concentrations can be observed after 1.7 hours of oral administration. Vildagliptin covalently binds to the catalytic site of DPP-4, which elicits prolonged enzyme inhibition. This, in turn, raises GLP-1 levels after meals or in a fasting state.

6. Is Vildagliptin safe for the liver?

Vildagliptin is a safe medicine for the liver. The meta-analysis indicates that Vildagliptin is not associated with an increased risk of hepatic enzyme elevation or hepatic events. So it is almost said that Vildagliptin is safe for the liver. However, there are few uncertainties about the long-term efficiency of Vildagliptin.

7. Is Vildagliptin better than Metformin?

Vildagliptin is a compelling and all-around endured treatment alternative in older patients with type 2 diabetes, exhibiting comparable improvement in glycaemic control as Metformin, with superior GI tolerability. Prandin, Canagliflozin, Dapagliflozin, Empagliflozin, Actos can be few other alternatives for Metformin.

8. Is Vildagliptin safe?

Vildagliptin use has been demonstrated as one of the relatively safest in clinical trials. However, the long-term efficiency or evaluation of safety data of the effects of DPP4 inhibition is compulsory. The DPP4 enzyme is present in many tissues in our body, which serves as a substrate for multiple hormones and peptides in the human body.

9. When should I take Vildagliptin?

It depends on the dosage. So, if you are prescribed to take one dosage a day, then it is better to take it in the morning. If you have two dosages, take one in the morning and the other in the evening. You can take these tablets before, during, or after the meals.

10. Is Vildagliptin safe for kidneys?

There is no deterioration of renal function observed with both Vildagliptin and Sitagliptin. Vildagliptin can be safely utilized in T2DM patients with changing levels of renal disability. Dosage changes for renal impedance are required. The expected long-term renal advantage of Vildagliptin should be further explored.



    • Yes Same as WhatsApp number

    • By clicking on Send, you accept to receive communication from Yashoda Hospitals on email, SMS, call and Whatsapp.


      • Yes Same as WhatsApp number

      • By clicking on Send, you accept to receive communication from Yashoda Hospitals on email, SMS, call and Whatsapp.

      Disclaimer: The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.